Evidence map›Paper›PMID 31531319›Full record

ArticleWorld journal of clinical cases2019

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy.

Mortada Hf El-Shabrawi, Laila M Sherief, Mostafa Yakoot, Naglaa M Kamal, Mohamed A Almalky, Manal M AbdElgawad, Aml A Mahfouz, Sherine Helmy, Enas M Kamal, Dina Attia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mortada Hf El-ShabrawiPaediatric Hepatology Department, Cairo Faculty of Medicine, Cairo 11559, Egypt.
Laila M SheriefPaediatric Hematology-Oncology Department, Zagazig Faculty of Medicine, Zagazig 21121, Egypt.
Mostafa YakootInternal medicine, Pediatrics and Hepatology, Green Clinic and Research Center, Alexandria University, Alexandria 21121, Egypt. yakoot@yahoo.com.
Naglaa M KamalPaediatric Hepatology Department, Cairo Faculty of Medicine, Cairo 11559, Egypt.
Mohamed A AlmalkyPaediatric Hematology-Oncology Department, Zagazig Faculty of Medicine, Zagazig 21121, Egypt.
Manal M AbdElgawadPaediatric Hepatology Department, Alexandria Faculty of medicine, Alexandria 21121, Egypt.
Aml A MahfouzPaediatric Hepatology Department, Alexandria Faculty of medicine, Alexandria 21121, Egypt.
Sherine HelmyInnovations & Research, Pharco Corporation, Alexandria 21121, Egypt.
Enas M KamalEndemic medicine and Hepatology Department, Minia University, Minia 22233, Egypt.
Dina AttiaEndemic medicine and Hepatology Department, Beni-suef University, Beni-suef 62511, Egypt.
Hisham R El-KhayatGastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo 23323, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildhood cancer survivors are potentially at a higher risk of infection with hepatitis C virus (HCV). The effects of all-oral direct-acting antiviral therapy (DAA) on both the HCV infection as well as the state of cancer remission have not been well investigated in this population.

aimTo test the effects of dual sofosbuvir/daclatasvir (SOF/DCV) therapy in the treatment of chronic HCV in survivors of hematologic malignancy in pediatric age group.

methodsWe conducted a prospective, uncontrolled, open-label multicenter study. A total of 20 eligible, chronic HCV, genotype-4, infected children who had been in continuous complete remission from hematologic cancer (leukemia/lymphoma) for at least one year were included in the study. All patients were treated with combined SOF/DCV for 12 wk. Patients were monitored throughout the study till 12 wk after end of treatment for safety and efficacy outcomes including the sustained virologic response 12 (SVR12) rate, hematological indices, liver and kidney functions.

resultsThe intent-to-treat SVR12 rate was 20 of 20 (100%; 95%CI: 84%-100%). All patients showed normalized liver enzymes from week-4. All hematological indices, liver and kidney functions were kept normal throughout the study. No fatalities or treatment-emergent serious or severe adverse events were reported throughout the study.

conclusionSOF/DCV combined therapy could be used safely and effectively in the treatment of chronic HCV genotype-4 infection in leukemia/lymphoma treated children. No relapses were detected during treatment and throughout the follow up period for either the original malignant disease or the HCV infection.

Indexed as

Chronic hepatitis CDaclatasvirEfficacySofosbuvirSurvivors of childhood cancer

Identifiers

PMID31531319
PMCPMC6718790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.